Navigation path

Intranasal H5vaccine

Vaccines and Correlates of Protection

Immumogenicity and Protective Efficacy of Intranasal DELNS1(H5N1) Influenza Vaccine

EC contribution
: € 2 680 400
: 36 months
Starting date
: 01/01/2007
: NS1, H5, avian influenza, vaccine, replication deficient, intranasal
Project Number
: SP5B-CT-2007-044512


In collaboration with six partners in four European countries and in Russia, Green Hills Biotechnology is developing a novel vaccine against avian influenza, within the framework of a research project subsidised by the European Union. The project budget totals EUR 2.6 million.

This project is being carried out by an international consortium over a three-year period. Besides Green Hills Biotechnology, a total of three other companies and three universities are participating in the development and evaluation of an intranasal H5 vaccine. The proposed vaccine is based on proprietary technology from Green Hills Biotechnology. Immunological properties will be assessed by the Goethe University in Frankfurt and preclinical experiments will be carried out at Biotest s.r.o. in the Czech Republic. Novel, sensitive methods developed for assessment of the antibody response against viral proteins are being established in cooperation with the Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry in Moscow. These assays will allow the selection of an optimal vaccine candidate that will be subsequently evaluated in clinical trials at the Medical University, Vienna, and at Retroscreen in the UK.

[+] Read More